Cargando…

Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial

The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yutao, Corica, Bernadette, Romiti, Giulio Francesco, Proietti, Marco, Zhang, Hui, Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017580/
https://www.ncbi.nlm.nih.gov/pubmed/36630000
http://dx.doi.org/10.1007/s11739-022-03188-2
_version_ 1784907621284708352
author Guo, Yutao
Corica, Bernadette
Romiti, Giulio Francesco
Proietti, Marco
Zhang, Hui
Lip, Gregory Y. H.
author_facet Guo, Yutao
Corica, Bernadette
Romiti, Giulio Francesco
Proietti, Marco
Zhang, Hui
Lip, Gregory Y. H.
author_sort Guo, Yutao
collection PubMed
description The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patients. Whether this benefit can be applied to both males and females is unclear, especially given the suboptimal management and poorer cardiovascular outcomes in females with AF. In this post-hoc analysis, we performed a sex-stratified analysis of the mAFA-II trial. Between June 2018 and August 2019, adult AF patients were enrolled across 40 centers in China. The primary outcome was the composite of stroke, thromboembolism, all-cause death, and re-hospitalization. The effect of mAFA intervention according to sex was evaluated through adjusted Cox-regression models. Among the 3,324 patients enrolled in the trial, 2,062 (62.0%) patients were males (mean age: 67.5 ± 14.3 years; 1,021 allocated to mAFA intervention) and 1,262 (38.0%) were females (mean age: 70.2 ± 13.0; 625 allocated to mAFA intervention). A significant risk reduction of the primary composite outcome in patients allocated to mAFA intervention was observed in both males (adjusted hazard ratio [aHR] and 95% confidence interval [CI] 0.30 [0.17–0.52]) and females (aHR [95%CI] 0.50 [0.27–0.92]), without statistically significant interaction (p = 0.225). Sex-based interactions were observed for other secondary outcomes, including all-cause death (p = 0.026) and bleeding events (p = 0.032). A mHealth-technology implemented ABC pathway was similarly effective in reducing the risk of adverse clinical events both in male and female patients. Secondary outcomes showed greater benefits of mAFA intervention in men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-03188-2.
format Online
Article
Text
id pubmed-10017580
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100175802023-03-17 Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial Guo, Yutao Corica, Bernadette Romiti, Giulio Francesco Proietti, Marco Zhang, Hui Lip, Gregory Y. H. Intern Emerg Med Im - Original The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster-randomized trial showed that a mobile health (mHealth)-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach reduced the risk of adverse events in atrial fibrillation (AF) patients. Whether this benefit can be applied to both males and females is unclear, especially given the suboptimal management and poorer cardiovascular outcomes in females with AF. In this post-hoc analysis, we performed a sex-stratified analysis of the mAFA-II trial. Between June 2018 and August 2019, adult AF patients were enrolled across 40 centers in China. The primary outcome was the composite of stroke, thromboembolism, all-cause death, and re-hospitalization. The effect of mAFA intervention according to sex was evaluated through adjusted Cox-regression models. Among the 3,324 patients enrolled in the trial, 2,062 (62.0%) patients were males (mean age: 67.5 ± 14.3 years; 1,021 allocated to mAFA intervention) and 1,262 (38.0%) were females (mean age: 70.2 ± 13.0; 625 allocated to mAFA intervention). A significant risk reduction of the primary composite outcome in patients allocated to mAFA intervention was observed in both males (adjusted hazard ratio [aHR] and 95% confidence interval [CI] 0.30 [0.17–0.52]) and females (aHR [95%CI] 0.50 [0.27–0.92]), without statistically significant interaction (p = 0.225). Sex-based interactions were observed for other secondary outcomes, including all-cause death (p = 0.026) and bleeding events (p = 0.032). A mHealth-technology implemented ABC pathway was similarly effective in reducing the risk of adverse clinical events both in male and female patients. Secondary outcomes showed greater benefits of mAFA intervention in men. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-03188-2. Springer International Publishing 2023-01-11 2023 /pmc/articles/PMC10017580/ /pubmed/36630000 http://dx.doi.org/10.1007/s11739-022-03188-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Im - Original
Guo, Yutao
Corica, Bernadette
Romiti, Giulio Francesco
Proietti, Marco
Zhang, Hui
Lip, Gregory Y. H.
Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title_full Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title_fullStr Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title_full_unstemmed Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title_short Efficacy of mobile health-technology integrated care based on the ‘Atrial fibrillation Better Care’ (ABC) pathway in relation to sex: a report from the mAFA-II randomized clinical trial
title_sort efficacy of mobile health-technology integrated care based on the ‘atrial fibrillation better care’ (abc) pathway in relation to sex: a report from the mafa-ii randomized clinical trial
topic Im - Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017580/
https://www.ncbi.nlm.nih.gov/pubmed/36630000
http://dx.doi.org/10.1007/s11739-022-03188-2
work_keys_str_mv AT guoyutao efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT coricabernadette efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT romitigiuliofrancesco efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT proiettimarco efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT zhanghui efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT lipgregoryyh efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial
AT efficacyofmobilehealthtechnologyintegratedcarebasedontheatrialfibrillationbettercareabcpathwayinrelationtosexareportfromthemafaiirandomizedclinicaltrial